MASH competitive intelligence · November 2026

MASH Competitive Intelligence Platform: Connecting Clinical Evidence, Competitive Positioning and Strategic Opportunity

An integrated intelligence framework connecting asset-level information, clinical development, mechanism analysis, competitive benchmarking and opportunity assessment across the evolving MASH landscape.

50+ MASH assets tracked 35+ sponsors Data cut-off: November 15, 2026 Get in Touch
50+MASH assets tracked
35+Sponsors with tracked assets
400+Competitive intelligence records
98.3%Tier 1 source validation

Understanding the Evolving MASH Competitive Landscape

Metabolic dysfunction-associated steatohepatitis (MASH) is becoming an increasingly competitive therapeutic area, with pharmaceutical companies advancing programs across multiple mechanisms, modalities and stages of clinical development.

As the pipeline expands, the challenge for pharmaceutical companies, biotechnology businesses and strategic investors is no longer limited to identifying which assets are in development.

Decision-makers need a structured understanding of the competitive landscape: who is developing what, how clinical evidence compares, which mechanisms are attracting investment, where development activity is concentrated and where opportunities may still exist.

To address this need, SPER Market Research has developed the MASH Competitive Intelligence Platform, bringing together asset intelligence, clinical development tracking, mechanism analysis, competitive benchmarking and opportunity assessment in one integrated intelligence framework.

Asset master Clinical landscape Mechanisms & targets Benchmarking Clinical readouts Milestones

A Structured Intelligence Platform Covering Six Dimensions

The platform is organised around six interconnected modules, designed to connect asset-level visibility with clinical evidence and strategic interpretation.

01

Asset Master

A consolidated view of 50+ MASH assets, including sponsors, development status, therapeutic approaches and key asset-level information.

02

Clinical Landscape

Structured visibility into the clinical development landscape, covering sponsors, trials, development phases and relevant clinical milestones.

03

Mechanism & Target Intelligence

Mapping of 30 mechanism classes, enabling analysis of therapeutic approaches, target concentration and emerging areas of development.

04

Competitive Benchmarking

Standardised comparisons of leading assets using available clinical evidence. Reported clinical facts are distinguished from company-reported claims and mixed evidence.

05

Clinical Readouts

A structured repository of clinical outcomes, including pivotal trial findings and relevant efficacy endpoints, with source traceability.

06

Regulatory & Milestone Intelligence

Tracking of important development and regulatory milestones to support ongoing competitive monitoring.

Platform Coverage at a Glance

The November 15, 2026 data cut-off includes:

50+MASH assets tracked
35+Sponsors with tracked assets
400+Competitive intelligence records
250+Cited sources
98.3%Tier 1 source validation
6Integrated intelligence modules

The underlying architecture separates raw source data, validated information and analyst interpretation. This is designed to improve traceability, make discrepancies visible and prevent analytical interpretations from being presented as established facts.

Moving Beyond Pipeline Tracking: Competitive Benchmarking

Clinical differentiation is central to understanding the MASH landscape.

The platform includes a structured benchmarking framework covering nine leading assets, with clinical outcomes organised around MASH resolution and relevant trial evidence.

The framework explicitly distinguishes reported facts, company claims and mixed evidence.

Evidence classification in competitive benchmarking
A structured approach to interpreting available clinical information
Evidence discipline

Reported clinical facts

Clinical information presented as reported in the available evidence and source material.

Company-reported claims

Claims attributed to company communications rather than treated as independently established clinical facts.

Mixed evidence is identified separately

The platform preserves distinctions in evidence type instead of blending different source categories into a single conclusion.

It also recognises that trials may differ in phase, duration, patient populations, endpoints and assessment methodology. Consequently, numerical comparisons should not automatically be interpreted as direct head-to-head evidence.

This distinction is particularly important when evaluating programs with Phase II results alongside assets supported by Phase III evidence or regulatory approval.

Identifying Where Competitive Opportunities Exist

Beyond understanding the existing pipeline, the platform incorporates an opportunity-scoring framework.

More than 50 assets are evaluated across four patient segments and three scenarios using a rule-based scoring methodology with five weighted criteria.

Current segment assessment: key opportunity signals
Selected findings from the platform's opportunity-scoring framework
Segment assessment

F4 cirrhosis-only

This segment has just three active assets and the highest headroom score in the current segment assessment, indicating a comparatively less crowded development landscape.

Headroom score: 56.7

Broad or unstaged MASH

Approximately 49% of active assets compete in this segment, making it the most contested area in the current assessment.

~49% of active assets

F2-F3 plus F4 cirrhosis

This segment records the highest opportunity score, although it already has five or more active programs.

Opportunity score: 77.0

These findings illustrate why pipeline volume alone is insufficient to determine strategic attractiveness. Competitive intensity and segment-specific headroom also matter.

Separating Market Attractiveness from Right-to-Win

An additional dimension of the platform is its Right-to-Win framework.

While opportunity scoring evaluates the attractiveness of assets and market segments, Right-to-Win assesses internal capability fit across different therapeutic modality families.

MARKET OPPORTUNITY How attractive is the segment? Assets · Competition · Headroom RIGHT-TO-WIN Can the organisation compete? Capabilities · Modalities · Platform fit

This distinction is important: an attractive market opportunity does not necessarily translate into an organisation's ability to compete successfully.

The framework is designed to support more disciplined strategic discussions around capability strengths, platform gaps and potential investment priorities.

Demonstration note

Right-to-Win scores in the demonstration are illustrative and reflect a demo-tenant assessment, not an independently established industry ranking.

Built Around Evidence Quality and Traceability

The platform follows a three-layer data architecture:

01 · Raw Data Layer

Source register and discrepancy log.

02 · Validated Data Layer

Primary and secondary source validation, validation status and rule-derived data confidence.

03 · Analyst Interpretation Layer

Clearly separated strategic interpretation, ensuring that analytical conclusions are not mixed with reported facts.

Each intelligence record is designed to maintain source traceability.

The current platform focuses specifically on competitive intelligence. Market sizing, revenue forecasting, pricing and epidemiology are outside its present scope.

The SPER Perspective

The MASH landscape will continue to evolve as clinical readouts, regulatory developments and new therapeutic mechanisms reshape competitive positioning.

For organisations operating in this space, the ability to connect asset-level information with clinical evidence and strategic opportunity assessment will become increasingly important.

At SPER Market Research, our objective is to build intelligence platforms that go beyond information aggregation.

We aim to connect the clinical, competitive and strategic dimensions of pharmaceutical markets, helping decision-makers move from understanding the landscape to identifying where meaningful opportunities may exist.

SPER Market Research

Turning Quality Research into Strategic Intelligence.

Platform-related enquiries

Looking to understand the MASH competitive landscape in greater depth?

Connect with SPER Market Research to discuss the MASH Competitive Intelligence Platform and explore how integrated asset, clinical and strategic intelligence can support your decision-making.

[email protected]

Email SPER Market Research
Thought Leadership

Trusted by Industry Leaders

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.

SPER-Astellas Pharma
SPER-Microsoft
SPER-EY
SPER-McKinsey
SPER-Bain
SPER-Max-Healthcare
SPER-DHL
SPER-IQVIA
SPER-Mitsubishi Logistics
SPER-PACCOR
SPER-Macmillan Education
SPER-Kankar IMRB
SPER-ITA
SPER-PWC
SPER-SAPTCA
SPER-Straumann
SPER-Danaher
SPER-AandM
SPER-MENARINI Silicon Biosystems
SPER-IPSOS
SPER-Heineken
HIPPA Compliant
GDPR Certified
ISO 27001
Peer Reviewed
Get Started Today

Your Competitive Advantage in
Pharmaceutical & Medical Technology
Markets

Join industry leaders leveraging AI-powered intelligence to make confident, data-driven decisions that accelerate breakthrough treatments and technologies to market.

No Credit Card Required
15-Minute Demo
Expert Guidance